The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
PET of Brain Amyloid and Tau in Mild Cognitive Impairment
Abstract
BACKGROUND: Amyloid senile plaques and tau neurofibrillary tangles are neuropathological hallmarks of Alzheimer's disease that accumulate in the cortical regions of the brain in persons with mild cognitive impairment who are at risk for Alzheimer's disease. Noninvasive methods to detect these abnormal proteins are potentially useful in developing surrogate markers for drug discovery and diagnostics. METHODS: We enrolled 83 volunteers with self-reported memory problems who had undergone neurologic and psychiatric evaluation and positron-emission tomography (PET). On the basis of cognitive testing, 25 volunteers were classified as having Alzheimer's disease, 28 as having mild cognitive impairment, and 30 as having no cognitive impairment (healthy controls). PET was performed after injection of 2-(1-{6-[(2-[F-18]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile (FDDNP), a molecule that binds to plaques and tangles in vitro. All subjects also underwent 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET, and 72 underwent magnetic resonance imaging (MRI). RESULTS: Global values for FDDNP-PET binding (average of the values for the temporal, parietal, posterior cingulate, and frontal regions) were lower in the control group than in the group with mild cognitive impairment (P<0.001), and the values for binding in the group with mild cognitive impairment were lower than in the group with Alzheimer's disease (P<0.001). FDDNP-PET binding differentiated among the diagnostic groups better than did metabolism on FDG-PET or volume on MRI. CONCLUSIONS: FDDNP-PET scanning can differentiate persons with mild cognitive impairment from those with Alzheimer's disease and those with no cognitive impairment. This technique is potentially useful as a noninvasive method to determine regional cerebral patterns of amyloid plaques and tau neurofibrillary tangles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Mild cognitive impairment as a diagnostic entity
Petersen, R. C. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01388.x · Cited by 7,864
Talairach, J., Tournoux, P., & Rayport, M. (1988) · Thieme eBooks · Cited by 5,058
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. ‐., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01380.x · Cited by 4,946
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data
Logan, J., Fowler, J. S., Volkow, N. D., Wang, G.-J., Ding, Y.-S., & Alexoff, D. L. (1996) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199609000-00008 · Cited by 1,514
Silverman, D. H. S., Small, G. W., Chang, C. Y., Lu, C. S., de Aburto, M. A. K., Chen, W., Czernin, J., Rapoport, S. I., Pietrini, P., Alexander, G. E., et al. (2001) · JAMA · doi:10.1001/jama.286.17.2120 · Cited by 951
Self-citation
Cited by
Molecular mechanisms and physiological functions of mitophagy
Onishi, M., Yamano, K., Sato, M., Matsuda, N., & Okamoto, K. (2021) · The EMBO Journal · doi:10.15252/embj.2020104705 · Cited by 1,416
Alzheimer disease: Epidemiology, diagnostic criteria, risk factors and biomarkers
Reitz, C., & Mayeux, R. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.024 · Cited by 1,181
Dickerson, B. C., Bakkour, A., Salat, D. H., Feczko, E., Pacheco, J., Greve, D. N., Grodstein, F., Wright, C. I., Blacker, D., Rosas, H. D., et al. (2009) · Cerebral Cortex · doi:10.1093/cercor/bhn113 · Cited by 1,153
Use of Florbetapir-PET for Imaging β-Amyloid Pathology
Clark, C. M. (2011) · JAMA · doi:10.1001/jama.2010.2008 · Cited by 1,117
Jack, C. R., Lowe, V. J., Senjem, M. L., Weigand, S. D., Kemp, B. J., Shiung, M. M., Knopman, D. S., Boeve, B. F., Klunk, W. E., Mathis, C. A., et al. (2008) · Brain · doi:10.1093/brain/awm336 · Cited by 958
“The most significant advance in dementia imaging in recent years has been the development of in vivo amyloid plaque labeling compounds (Klunk et al., 2004; Small et al., 2006; Verhoeff et al., 2004).”
BackgroundPost-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., et al. (2008) · Brain · doi:10.1093/brain/awn016 · Cited by 933
“Positron emission tomography (PET) imaging of amyloid deposits (Klunk et al., 2004; Verhoeff et al., 2004; Small et al., 2006) employs blood–brain barrier penetrant amyloid-binding compounds such as the thioflavin-T derivative Pittsburgh Compound-B (PiB) (Klunk et al., 2001, 2004; Mathis et al.,…”
BackgroundMaruyama, M., Shimada, H., Suhara, T., Shinotoh, H., Ji, B., Maeda, J., Zhang, M.-R., Trojanowski, J. Q., Lee, V. M.-Y., Ono, M., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.07.037 · Cited by 760
Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease
Brier, M. R., Gordon, B., Friedrichsen, K., McCarthy, J., Stern, A., Christensen, J., Owen, C., Aldea, P., Su, Y., Hassenstab, J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2362 · Cited by 734
PET imaging of amyloid deposition in patients with mild cognitive impairment
Forsberg, A., Engler, H., Almkvist, O., Blomquist, G., Hagman, G., Wall, A., Ringheim, A., Långström, B., & Nordberg, A. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.03.029 · Cited by 728
Multimodal techniques for diagnosis and prognosis of Alzheimer's disease
Perrin, R. J., Fagan, A. M., & Holtzman, D. M. (2009) · Nature · doi:10.1038/nature08538 · Cited by 702
Wong, D. F., Rosenberg, P. B., Zhou, Y., Kumar, A., Raymont, V., Ravert, H. T., Dannals, R. F., Nandi, A., Brašić, J. R., Ye, W., et al. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.069088 · Cited by 684
Rowe, C. C., Ackerman, U., Browne, W., Mulligan, R., Pike, K. L., O'Keefe, G., Tochon-Danguy, H., Chan, G., Berlangieri, S. U., Jones, G., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70001-2 · Cited by 671
The Episodic Memory System: Neurocircuitry and Disorders
Dickerson, B. C., & Eichenbaum, H. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.126 · Cited by 657
18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial
Vandenberghe, R., Van Laere, K., Ivanoiu, A., Salmon, E., Bastin, C., Triau, E., Hasselbalch, S., Law, I., Andersen, A., Korner, A., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22068 · Cited by 646
Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study
Sabri, O., Sabbagh, M. N., Seibyl, J., Barthel, H., Akatsu, H., Ouchi, Y., Senda, K., Murayama, S., Ishii, K., Takao, M., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.02.004 · Cited by 602
Tau PET imaging in neurodegenerative tauopathies—still a challenge
Leuzy, A., Chiotis, K., Lemoine, L., Gillberg, P.-G., Almkvist, O., Rodriguez-Vieitez, E., & Nordberg, A. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0342-8 · Cited by 628
Cohen, R. M., Rezai-Zadeh, K., Weitz, T. M., Rentsendorj, A., Gate, D., Spivak, I., Bholat, Y., Vasilevko, V., Glabe, C. G., Breunig, J. J., et al. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.3672-12.2013 · Cited by 531
Self-citationTau imaging: early progress and future directions
Villemagne, V. L., Fodero-Tavoletti, M. T., Masters, C. L., & Rowe, C. C. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70252-2 · Cited by 501
Imaging of amyloid burden and distribution in cerebral amyloid angiopathy
Johnson, K. A., Gregas, M., Becker, J. A., Kinnecom, C., Salat, D. H., Moran, E. K., Smith, E. E., Rosand, J., Rentz, D. M., Klunk, W. E., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21164 · Cited by 495
The use of PET in Alzheimer disease
Nordberg, A., Rinne, J. O., Kadir, A., & Långström, B. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.217 · Cited by 449
Early diagnosis of Alzheimer's disease using cortical thickness: impact of cognitive reserve
Querbes, O., Aubry, F., Pariente, J., Lotterie, J.-A., Démonet, J.-F., Duret, V., Puel, M., Berry, I., Fort, J.-C., Celsis, P., et al. (2009) · Brain · doi:10.1093/brain/awp105 · Cited by 444
Ghetti, B., Oblak, A. L., Boeve, B. F., Johnson, K. A., Dickerson, B. C., & Goedert, M. (2015) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12213 · Cited by 438
Preclinical Properties of 18F-AV-45: A PET Agent for Aβ Plaques in the Brain
Choi, S. R., Golding, G., Zhuang, Z., Zhang, W., Lim, N., Hefti, F., Benedum, T. E., Kilbourn, M. R., Skovronsky, D., & Kung, H. F. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.065284 · Cited by 431
De-Paula, V. J., Radanovic, M., Diniz, B. S., & Forlenza, O. V. (2012) · Subcellular Biochemistry · doi:10.1007/978-94-007-5416-4_14 · Cited by 405
Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer's disease
Desikan, R. S., Cabral, H. J., Hess, C. P., Dillon, W. P., Glastonbury, C. M., Weiner, M. W., Schmansky, N. J., Greve, D. N., Salat, D. H., Buckner, R. L., et al. (2009) · Brain · doi:10.1093/brain/awp123 · Cited by 405
Klunk, W. E., Price, J. C., Mathis, C. A., Tsopelas, N. D., Lopresti, B. J., Ziolko, S. K., Bi, W., Hoge, J. A., Cohen, A. D., Ikonomovic, M. D., et al. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0730-07.2007 · Cited by 389
Devanand, D. P., Liu, X., Tabert, M. H., Pradhaban, G., Cuasay, K., Bell, K., de Leon, M. J., Doty, R. L., Stern, Y., & Pelton, G. H. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.06.020 · Cited by 397
Amsterdam Dementia Cohort: Performing Research to Optimize Care
van der Flier, W. M., & Scheltens, P. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170850 · Cited by 390
Total and phosphorylated tau protein as biological markers of Alzheimer’s disease
Hampel, H., Blennow, K., Shaw, L. M., Hoessler, Y. C., Zetterberg, H., & Trojanowski, J. Q. (2010) · Experimental Gerontology · doi:10.1016/j.exger.2009.10.010 · Cited by 389
Cerebral amyloid angiopathy and its relationship to Alzheimer’s disease
Thal, D. R., Griffin, W. S. T., de Vos, R. A. I., & Ghebremedhin, E. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0366-2 · Cited by 372
Chételat, G., La Joie, R., Villain, N., Perrotin, A., de La Sayette, V., Eustache, F., & Vandenberghe, R. (2013) · NeuroImage: Clinical · doi:10.1016/j.nicl.2013.02.006 · Cited by 352
Small, G. W., Siddarth, P., Li, Z., Miller, K. J., Ercoli, L., Emerson, N. D., Martinez, J., Wong, K.-P., Liu, J., Merrill, D. A., et al. (2018) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2017.10.010 · Cited by 350
Self-citationAmyloid imaging in mild cognitive impairment subtypes
Wolk, D. A., Price, J. C., Saxton, J. A., Snitz, B. E., James, J. A., Lopez, O. L., Aizenstein, H. J., Cohen, A. D., Weissfeld, L. A., Mathis, C. A., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21598 · Cited by 339
Nelissen, N., Van Laere, K., Thurfjell, L., Owenius, R., Vandenbulcke, M., Koole, M., Bormans, G., Brooks, D. J., & Vandenberghe, R. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.063305 · Cited by 330
Alzheimer's Disease and Mild Cognitive Impairment
Kelley, B. J., & Petersen, R. C. (2007) · Neurologic Clinics · doi:10.1016/j.ncl.2007.03.008 · Cited by 326
Wright, A. L., Zinn, R., Hohensinn, B., Konen, L. M., Beynon, S. B., Tan, R. P., Clark, I. A., Abdipranoto, A., & Vissel, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059586 · Cited by 313
PIB is a non-specific imaging marker of amyloid-beta (A ) peptide-related cerebral amyloidosis
Lockhart, A., Lamb, J. R., Osredkar, T., Sue, L. I., Joyce, J. N., Ye, L., Libri, V., Leppert, D., & Beach, T. G. (2007) · Brain · doi:10.1093/brain/awm191 · Cited by 302
“, 2004) and [18F]-FDDNP (Shoghi-Jadid et al., 2002; Small et al., 2006) are currently undergoing evaluation studies in dementia populations; understanding their molecular binding profile using analogous experimental procedures will be critical in evaluating their potential as imaging biomarkers.”
BackgroundMethodβ-Amyloid, Blood Vessels, and Brain Function
Smith, E. E., & Greenberg, S. M. (2009) · Stroke · doi:10.1161/strokeaha.108.536839 · Cited by 293
Jacobs, H. I. L., Van Boxtel, M. P. J., Jolles, J., Verhey, F. R. J., & Uylings, H. B. M. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.06.009 · Cited by 293
Positron emission tomography imaging in dementia
HERHOLZ, K., CARTER, S. F., & JONES, M. (2007) · The British Journal of Radiology · doi:10.1259/bjr/97295129 · Cited by 287
Disease-modifying therapies for Alzheimer disease: Challenges to early intervention
Cummings, J. L., Doody, R., & Clark, C. (2007) · Neurology · doi:10.1212/01.wnl.0000295996.54210.69 · Cited by 279
Non-invasive assessment of Alzheimer’s disease neurofibrillary pathology using 18F-THK5105 PET
Okamura, N., Furumoto, S., Fodero-Tavoletti, M. T., Mulligan, R. S., Harada, R., Yates, P., Pejoska, S., Kudo, Y., Masters, C. L., Yanai, K., et al. (2014) · Brain · doi:10.1093/brain/awu064 · Cited by 264
Ng, S., Villemagne, V. L., Berlangieri, S., Lee, S.-T., Cherk, M., Gong, S. J., Ackermann, U., Saunder, T., Tochon-Danguy, H., Jones, G., et al. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.037762 · Cited by 258
THOMPSON, P. M., HAYASHI, K. M., DUTTON, R. A., CHIANG, M., LEOW, A. D., SOWELL, E. R., DE ZUBICARAY, G., BECKER, J. T., LOPEZ, O. L., AIZENSTEIN, H. J., et al. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1379.017 · Cited by 253
Self-citationUsing PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment
Camus, V., Payoux, P., Barré, L., Desgranges, B., Voisin, T., Tauber, C., La Joie, R., Tafani, M., Hommet, C., Chételat, G., et al. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-2021-8 · Cited by 252
Mosconi, L., De Santi, S., Brys, M., Tsui, W. H., Pirraglia, E., Glodzik-Sobanska, L., Rich, K. E., Switalski, R., Mehta, P. D., Pratico, D., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.030 · Cited by 238
Beta‐amyloid deposition and the aging brain
Rodrigue, K. M., Kennedy, K. M., & Park, D. C. (2009) · Neuropsychology Review · doi:10.1007/s11065-009-9118-x · Cited by 230
“Similarly, 18F-FDDNP also successfully labels amyloid plaques (Small et al. 2006), but may do so in a different manner than PIB (Tolboom et al.”
BackgroundMethodInfluentialChoo, I. H., Lee, D. Y., Oh, J. S., Lee, J. S., Lee, D. S., Song, I. C., Youn, J. C., Kim, S. G., Kim, K. W., Jhoo, J. H., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.06.015 · Cited by 211
Li, H., Hou, X., Liu, H., Yue, C., He, Y., & Zuo, X. (2015) · Human Brain Mapping · doi:10.1002/hbm.22689 · Cited by 196
Wolk, D. A. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.153 · Cited by 156
Mosconi, L., Rinne, J. O., Tsui, W. H., Berti, V., Li, Y., Wang, H., Murray, J., Scheinin, N., Någren, K., Williams, S., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914141107 · Cited by 135
Thal, D. R., Griffin, W. S. T., & Braak, H. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00411.x · Cited by 134
“The pattern of A detected with these imaging methods is similar to that seen after autopsy [17, 19, 129, 132–134].”
MethodHall, B., Mak, E., Cervenka, S., Aigbirhio, F. I., Rowe, J. B., & O’Brien, J. T. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.03.002 · Cited by 132
PET Imaging of Neuropathology in Tauopathies: Progressive Supranuclear Palsy
Kepe, V., Bordelon, Y., Boxer, A., Huang, S.-C., Liu, J., Thiede, F. C., Mazziotta, J. C., Mendez, M. F., Donoghue, N., Small, G. W., et al. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-130032 · Cited by 106
Self-citationGarcez, M. L., Mina, F., Bellettini-Santos, T., Carneiro, F. G., Luz, A. P., Schiavo, G. L., Andrighetti, M. S., Scheid, M. G., Bolfe, R. P., & Budni, J. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.03.010 · Cited by 102
Cascaded multi-modal mixing transformers for Alzheimer’s disease classification with incomplete data
Liu, L., Liu, S., Zhang, L., To, X. V., Nasrallah, F., & Chandra, S. S. (2023) · NeuroImage · doi:10.1016/j.neuroimage.2023.120267 · Cited by 101
Yaribeygi, H., Rashidy-Pour, A., Atkin, S. L., Jamialahmadi, T., & Sahebkar, A. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118645 · Cited by 96
Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease
Vandenberghe, R., Adamczuk, K., Dupont, P., Laere, K. V., & Chételat, G. (2013) · NeuroImage: Clinical · doi:10.1016/j.nicl.2013.03.014 · Cited by 99
“, 2010), and the naphthol (18)F-FDDNP (Small et al., 2006).”
BackgroundThal, D. R., Attems, J., & Ewers, M. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-141461 · Cited by 100
A diffusion tensor MRI study of patients with MCI and AD with a 2-year clinical follow-up
Scola, E., Bozzali, M., Agosta, F., Magnani, G., Franceschi, M., Sormani, M. P., Cercignani, M., Pagani, E., Falautano, M., Filippi, M., et al. (2010) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.189639 · Cited by 98
Molecular imaging of neuroinflammation in Alzheimer's disease and mild cognitive impairment
Knezevic, D., & Mizrahi, R. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.05.007 · Cited by 97
“The progression from MCI to dementia is 10–15% per year, which is significantly higher compared to the general population with an estimated conversion rate of 1–2% per year (Small et al., 2006).”
Nuclear medicine and molecular imaging advances in the 21st century
Vaz, S. C., Oliveira, F., Herrmann, K., & Veit-Haibach, P. (2020) · The British Journal of Radiology · doi:10.1259/bjr.20200095 · Cited by 86
Laforce, R., & Rabinovici, G. D. (2011) · Alzheimer's Research & Therapy · doi:10.1186/alzrt93 · Cited by 79
Biomarkers in translational research of Alzheimer’s Disease
Tarawneh, R., & Holtzman, D. M. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.04.006 · Cited by 67
Yang, D., Xie, Z., Stephenson, D., Morton, D., Hicks, C. D., Brown, T. M., Sriram, R., O'Neill, S., Raunig, D., & Bocan, T. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2010.10.067 · Cited by 64
“As the genetics of AD implicate Aβ amyloid in disease pathogenesis, much effort has focused in recent years on developing positron emission tomography (PET) ligands capable of quantifying amyloid load as a potential disease progression biomarker (Klunk et al., 2004; Kudo et al., 2007; Small et al., 2006).”
BackgroundZhou, Y., & Lui, Y. W. (2013) · ISRN Geriatrics · doi:10.1155/2013/542080 · Cited by 44
Tau in Late-Life Depression: A Systematic Review and Meta-Analysis
Brown, E. E., Iwata, Y., Chung, J. K., Gerretsen, P., & Graff-Guerrero, A. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160401 · Cited by 29
Alzheimer's disease biomarkers: correspondence between human studies and animal models
Sabbagh, J. J., Kinney, J. W., & Cummings, J. L. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.04.010 · Cited by 27
Metadata
- Authors
- Small, G. W., Kepe, V., Ercoli, L. M., Siddarth, P., Bookheimer, S. Y., Miller, K. J., Lavretsky, H., Burggren, A. C., Cole, G. M., Vinters, H. V., Thompson, P. M., Huang, S.-C., Satyamurthy, N., Phelps, M. E., & Barrio, J. R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-12-21
- Volume
- 355
- Issue
- 25
- Pages
- 2652-2663
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2163057869
- Cited by
- 738
- References
- 29
- FWCI
- 53.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.